Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$15.86 USD

15.86
277,594

-0.15 (-0.94%)

Updated May 17, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cooper Companies' (COO) CooperVision Gains Momentum Globally

by Zacks Equity Research

Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

National Vision (EYE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision (EYE) Q3 Earnings Match Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 0.00% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.

Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?

by Zacks Equity Research

Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

    What's in Store for Penumbra (PEN) This Earnings Season?

    by Zacks Equity Research

    Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.

      Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?

      by Zacks Equity Research

      Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.

        4 Toxic Stocks to Discard or Sell Short for Solid Gains

        by Zacks Equity Research

        Overblown toxic stocks are usually vulnerable to outside shocks and loaded with a high level of debt.